Advertisement
Document › Details
MedinCell S.A.. (5/27/20). "Press Release: MedinCell Secures €10.9 Million Non-Dilutive Financing". Montpellier.
Region | France | |
Organisation | MedinCell S.A. (Euronext: MEDCL) | |
Group | MedinCell (Group) | |
Organisation 2 | Banque Populaire du Sud | |
Product | BEPO® technology | |
Product 2 | finance | |
Index term | MedinCell–SEVERAL: credit, 202005– state guaranteed PGE loan €10.9m at 0.25% up to 5y from Banque Populaire du Sud + BNP Paribas | |
Person | Arango, Jaime (MedinCell 202005 CFO) | |
Person 2 | Heuzé, David (MedinCell 202005 Corporate Communications) | |
€10.9 million loan to increase the Company's financial visibility
Loan taken out with Banque Populaire du Sud and BNP Paribas in the form of PGE
Annual results for the FY ended March 31, 2020 will be published on June 4, 2020, after market close. As a reminder, a dedicated videoconference will be held at this occasion on Thursday, June 4:
> 6.30 pm CEST – Presentation and Q&A in French
> 7.30 pm CEST – Presentation and Q&A in English
> Link to connect (only via internet): invest.medincell.com/conference
"We have maintained all operations related to strategic research and development programs since the beginning of the Coronavirus crisis, but other activities have been delayed," said Jaime Arango, Chief Financial Officer of MedinCell.
"Thanks to our partner banks who quickly mobilized to grant us this loan, we will be able to gradually return to normal activity level and advance as quickly as possible our Covid-19 program, which aims to develop a preventive treatment against the virus (prophylaxis)."
"The second half of the year should be rich for MedinCell, with potential milestones for several products based on our BEPO® technology currently in clinical studies. "
The loan is structured as a PGE (State Guaranteed Loan) with an initial maturity of 12 months at a 0,25% rate and an option for up to 5 years extension.
About MedinCell
MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.
Contacts
MedinCell
David Heuzé
Communication leader
david.heuze@medincell.com
+33 (0)6 83 25 21 86
NewCap
Louis-Victor Delouvrier
Relation investisseurs
medincell@newcap.eu
+33 (0)1 44 71 98 53
NewCap
Nicolas Merigeau
Relations médias
medincell@newcap.eu
+33 (0)1 44 71 94 98
Record changed: 2023-06-05 |
Advertisement
More documents for MedinCell (Group)
- [1] MedinCell S.A.. (4/16/24). "Press Release: Medincell Enters into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies". Montpellier....
- [2] MedinCell S.A.. (11/30/22). "Press Release: Additional US$ 4 Million Received for Next Development Steps of MedinCell’s 6-month Active Injectable Bioresorbable Subcutaneous Contraceptive". Montpellier....
- [3] MedXCell S.A.. (3/11/22). "Press Release: MedXCell SA Is Proud to Annonce the Arrival of Andrew Galzaka and John D. McMannis as New Members of the Board and Pierre J.Magistretti as New Scientific Advisor". Montreux....
- [4] MedXCell S.A.. (6/4/21). "Press Release: MedXCell SA Has Successfully Closed a CHF 5.3 Million Series A". Montreux....
- [5] MedinCell S.A.. (2/11/21). "Press Release: Tremendous Success for MedinCell’s €30 Million Capital Increase for Qualified Investors". Montpellier....
- [6] MedinCell S.A.. (6/16/20). "Press Release: MedinCell Announces the Great Success of Its Capital Increase and Raises 15.6 M€ [Not for publication nor to distribution in the United States, Canada, Japan or Australia]". Montpellier....
- [7] MedinCell S.A.. (3/25/20). "Press Release: MedinCell Receives $ 6.4 Million Grant from Unitaid to Fight Malaria". Montpellier....
- [8] MedinCell S.A.. (11/28/19). "Press Release: MedinCell Receives $19 Million Grant for Its mdc-WWM Program". Montpellier....
- [9] Euronext N.V.. (10/8/18). "Press Release: Medincell Lists on Euronext Paris. €30 Million Raised, Market Capitalisation €144 Million". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top